Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WSK-V104
- Development stage
- Preclinical
- Lead developer
- WestVac Biopharma
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
WSK-V104 is an adjuvanted recombinant trivalent influenza vaccine jointly developed by WestVac Biopharma and West China Hospital of Sichuan University for prevention of seasonal influenza. The vaccine is produced using an insect cell-baculovirus recombinant protein expression system rather than egg-based influenza-virus cultivation and is designed to match World Health Organization-recommended trivalent seasonal influenza strains. WestVac states that the product incorporates the novel adjuvant WGa01 to enhance and prolong vaccine-induced protective immune responses. WSK-V104 received National Medical Products Administration clinical-trial authorization in China on February 9, 2026.
- Other names
- Recombinant trivalent influenza vaccine
Beyond the preview
Go deeper on WSK-V104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WSK-V104.